Roles of four targets in the pathogenesis of graves' orbitopathy

Area of Science:

• Immunology and Endocrinology
• Ophthalmology and Autoimmune Diseases

Background:

• Graves' orbitopathy (GO) is a complex autoimmune disorder impacting the eyes, involving intricate immune system interactions.
• Current treatments, including surgery and non-specific/targeted drug therapies (e.g., tocilizumab, rituximab), have limitations in efficacy and side effect profiles.
• Teprotumumab, targeting IGF-IR, shows promise but the underlying pathophysiology of GO remains incompletely understood.

Purpose of the Study:

• To explore the pathogenesis of Graves' orbitopathy (GO) by examining immune cell and fibroblast interactions.
• To identify and highlight novel potential therapeutic targets for GO beyond existing treatment modalities.
• To deepen the understanding of immune response feedback pathways in GO for improved clinical management.

Main Methods:

• Review and discussion of the current understanding of GO pathogenesis.
• Exploration of immune system components and fibroblast roles in disease development.
• Identification and analysis of potential novel therapeutic targets based on disease mechanisms.

Main Results:

• The pathophysiology of GO involves complex interactions between immune cells and fibroblasts, with ongoing uncertainty.
• Existing targeted therapies like tocilizumab and rituximab demonstrate limited efficacy and potential side effects.
• Four promising potential therapeutic targets for GO have been identified: IL-23R, LepR, Orbital fibroblast activating factors, and PAI-1.

Conclusions:

• A comprehensive understanding of GO pathogenesis and immune signaling pathways is essential for developing effective treatments.
• Targeting novel pathways, including IL-23R, LepR, Orbital fibroblast activating factors, and PAI-1, may offer improved therapeutic strategies for GO patients.
• Further research into these potential targets is crucial for advancing the clinical management of Graves' orbitopathy.